Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the press release issued on March 14, 2025, titled “Court of Appeal convicts former employees – Peptonic Medical AB ordered to pay corporate fine”, was mistakenly labeled under the EU Market Abuse Regulation (MAR). As the ruling was already public, the information is not subject to MAR.
The press release concerned the Court of Appeal’s conviction of two former employees for aggravated insider trading related to their actions in connection with a financing arrangement in the spring of 2019. These events have no connection to the Company’s current board or management. Since the ruling was already public, it does not fall under MAR. The press release also stated that, as a consequence of the convicted individuals’ actions, the Company has been ordered to pay a corporate fine of SEK 500,000.
For further information, please contact:
Anna Linton, VD Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
